Kevin D. Freeman's most recent trade in Galectin Therapeutics Inc was a trade of 60,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | D. Freeman Kevin | Director | Purchase of securities on an exchange or from another person at price $ 0.81 per share. | 24 Dec 2024 | 10,000 | 44,769 (0%) | 0% | 0.8 | 8,134 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.64 per share. | 17 Oct 2024 | 1,300 | 34,769 (0%) | 0% | 2.6 | 3,432 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.70 per share. | 16 Oct 2024 | 5,000 | 80,000 (0%) | 0% | 2.7 | 13,500 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.70 per share. | 16 Oct 2024 | 5,000 | 33,469 (0%) | 0% | 2.7 | 13,500 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.38 per share. | 20 Jun 2024 | 2,500 | 28,469 (0%) | 0% | 2.4 | 5,950 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.98 per share. | 22 Apr 2024 | 2,500 | 25,969 (0%) | 0% | 3.0 | 7,450 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | 09 Apr 2024 | 2,063 | 18,063 (0%) | 0% | 0 | Common Stock | ||
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.41 per share. | 28 Oct 2022 | 10,000 | 75,000 (0%) | 0% | 1.4 | 14,100 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 19 May 2022 | 5,000 | 65,000 (0%) | 0% | 1.3 | 6,650 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.71 per share. | 18 Apr 2022 | 5,000 | 60,000 (0%) | 0% | 1.7 | 8,550 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.96 per share. | 19 Jan 2022 | 5,000 | 55,000 (0%) | 0% | 2.0 | 9,806 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 15 Dec 2021 | 5,000 | 50,000 (0%) | 0% | 2.3 | 11,400 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.34 per share. | 06 Dec 2021 | 5,000 | 45,000 (0%) | 0% | 2.3 | 11,700 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.17 per share. | 29 Oct 2021 | 2,000 | 40,000 (0%) | 0% | 3.2 | 6,340 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 21 Oct 2021 | 2,000 | 38,000 (0%) | 0% | 3.2 | 6,380 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.37 per share. | 19 Oct 2021 | 3,000 | 36,000 (0%) | 0% | 3.4 | 10,107 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.88 per share. | 23 Sep 2021 | 3,000 | 33,000 (0%) | 0% | 3.9 | 11,631 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 05 Apr 2021 | 5,000 | 30,000 (0%) | 0% | 2.0 | 10,200 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.57 per share. | 04 Sep 2020 | 5,000 | 25,000 (0%) | 0% | 2.6 | 12,848 | Common Stock |